Global Cardiology Academy

Welcome to Global
Cardiology Academy

Enhance your cardiology practice with CME and
tools focused on heart health management.

Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Heart Matters
Understanding Lipid and Lipoprotein Metabolism in Cardiovascular Health
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Heart Matters
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Heart Matters
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
CME/CE
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
0.25 credits
- John McMurray, MD
- Scott Solomon, MD
0.25 credits
Optimizing Patient Outcomes in CKD & T2D Care With CONFIDENCE
Optimizing Patient Outcomes in CKD & T2D Care With CONFIDENCE
Endocrinology
Optimizing Patient Outcomes in CKD & T2D Care With CONFIDENCE
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
Cardiology
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
- Justin Ezekowitz, MD, MBBCh, MSc
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
Cardiology
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
- Stephen Greene
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches
Heart Matters
Managing Cholesterol and Triglyceride Levels: Targeted Nutritional Approaches

Programs

Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
CME/CE
Behind the Screens: Innovations in Type 1 Diabetes Clinical Trials—From Immunomodulation to Screening Strategies and Advanced Cell Therapies
- Irene Caruso
Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
Cardiology
Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
- Javed Butler, MD, MPH, MBA
Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Heart Matters
Managing Statin Intolerance: Practical Approaches and Emerging Non-Statin Options
Improving Lipid Management Through Equity-Focused Clinical Strategies
Improving Lipid Management Through Equity-Focused Clinical Strategies
Heart Matters
Improving Lipid Management Through Equity-Focused Clinical Strategies
Integrating Lipoprotein(a) Into Cardiovascular Risk Assessment
Integrating Lipoprotein(a) Into Cardiovascular Risk Assessment
Heart Matters
Integrating Lipoprotein(a) Into Cardiovascular Risk Assessment
PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
Heart Matters
PCSK9 Inhibitors and Statins: Meta-Analysis Highlights Benefit of Combination Therapy
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
CME/CE
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
0.25 credits
- Amy Mottl, MD, MPH
- Prof. Christoph Wanner
0.25 credits
Statins and Safety: What the Data Say About Dementia, Cancer, and More
Statins and Safety: What the Data Say About Dementia, Cancer, and More
MinuteCE®
Statins and Safety: What the Data Say About Dementia, Cancer, and More
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit

Clinical Practice

EASD Highlights: Prediabetes Diagnosis, Prevalence, Misclassification Risks, and the Potential for Remission
EASD Highlights: Prediabetes Diagnosis, Prevalence, Misclassification Risks, and the Potential for Remission
Diabetes and Endocrinology
EASD Highlights: Prediabetes Diagnosis, Prevalence, Misclassification Risks, and the Potential for Remission
- Femke Rutters, MD
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
CME/CE Broadcast Replay
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
0.50 credits
- Prof. Ulrich Laufs
- Pam R. Taub, MD, FACC, FASPC
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Christie Ballantyne, MD
0.50 credits
New Insights in the Management of HCM: Exploring the Clinical Spectrum
New Insights in the Management of HCM: Exploring the Clinical Spectrum
CME/CE Broadcast Replay
New Insights in the Management of HCM: Exploring the Clinical Spectrum
0.50 credits
- Milind Y. Desai, MD, MBA
- Iacopo Olivotto, MD
- Elena Arbelo, MD, PhD
0.50 credits
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
Cardiology
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
- Carolyn Lam, MD
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
CME/CE
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
- Daniel Judge, MD
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Cardiology
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
- Javed Butler, MD
The Future of Precision Medicine in COPD Care: Biomarkers, AI, and Multimodal Data
The Future of Precision Medicine in COPD Care: Biomarkers, AI, and Multimodal Data
Pulmonary Medicine
The Future of Precision Medicine in COPD Care: Biomarkers, AI, and Multimodal Data
- Matthew Moll, MD, MPH
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
Cardiology
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
- Raymond Wade, MD

CME

Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CE
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
0.50 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Amy Mottl, MD, MPH
- Muthiah Vaduganathan, MD, MPH
0.50 credits
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
CME/CE
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
- Ahmad Masri, MD, MS
When and Why to Use CAC Scoring
When and Why to Use CAC Scoring
MinuteCE®
When and Why to Use CAC Scoring
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
MinuteCE®
Where Does This Patient Land? Making Sense of Risk and LDL-C Goals
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
MinuteCE®
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
1.00 program credit
- Rishi Wadhera, MD, MPP, Mphil
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
1.00 program credit
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
0.25 credits
- Riccardo Maria Inciardi, MD, PhD
0.25 credits
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
MinuteCE®
Unmasking Hidden Risk: The Role of Lp(a) in Cardiovascular Risk Assessment
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)
Impact of Finerenone on eGFR Slope by Baseline Albuminuria in FINEARTS-HF
- Finnian R. McCausland, MD